$MIST

Milestone Pharmaceuticals Inc. has filed its definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Shareholders, to be held virtually on June 10, 2026. Shareholders will vote on the election of eight directors, the ratification of PricewaterhouseCoopers LLP as auditor, an increase of 6,800,000 shares under the 2019 Equity Incentive Plan, and a non-binding advisory vote on executive compensation. The Board recommends voting FOR all proposals, emphasizing strong governance practices and the need for additional shares to attract and retain talent, especially following the FDA approval of CARDAMYST™.